<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04593979</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12406 EvvA</org_study_id>
    <nct_id>NCT04593979</nct_id>
  </id_info>
  <brief_title>ANRS 12406 EvvA Study</brief_title>
  <acronym>EvvA</acronym>
  <official_title>Virological Failure and HIV Drug Resistance Among Adolescents Receiving Antiretroviral Treatment in Cameroon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Laquinitinie de Douala</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Franceville International Center for Medical Research, Gabon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ANRS 12406 EvvA is an observational, longitudinal and monocentric study evaluating the&#xD;
      virological success rate in HIV-infected adolescents on antiretroviral therapy in Cameroon.&#xD;
&#xD;
      The main objective of the study is to estimate the rate of virological suppression among&#xD;
      adolescents on antiretroviral therapy for more than 6 months in Cameroon&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the end of 2017, HIV-AIDS affects more than 36 million people worldwide, more than&#xD;
      three-quarters of whom live in sub-Saharan Africa, and a quarter of the infections are among&#xD;
      young people and adolescents. Every hour, 4 adolescents (aged 15-19) are newly infected with&#xD;
      HIV in the world, and 3 of them are adolescents. Three infections occur in sub-Saharan&#xD;
      Africa, and for five adolescents living with HIV, there are seven girls (aged 10 to 19) in&#xD;
      the same situation. This gender disparity increases when adolescents reach adulthood. This&#xD;
      group of the population may well deserve the term &quot;key and vulnerable population&quot;. In the era&#xD;
      of international commitment to end the AIDS epidemic by 2030, especially to stop new&#xD;
      infections, it is essential not to neglect part of the epidemic because it would effectively&#xD;
      represent a reservoir for maintaining the epidemic and make these eradication goals&#xD;
      impracticable. Data on virological success among adolescents on antiretroviral treatment are&#xD;
      generally scarce and this is much more striking in Central Africa. Also, information on the&#xD;
      frequency of emergence of resistant viruses and the consequences for the effectiveness of&#xD;
      available treatments is rare. However, in the absence of such data, it is difficult, if not&#xD;
      impossible, to take the right decisions to improve the care and monitoring of adolescents. In&#xD;
      addition, the few available data indicate high virological failure rates and high frequencies&#xD;
      of drug resistance, which may indicate a need to further investigate virological failure&#xD;
      events in this population.&#xD;
&#xD;
      This study will be conducted in Cameroon among 289 adolescents during 9 months, where access&#xD;
      to biological monitoring is a major challenge, especially with low access to viral load&#xD;
      testing. The results of this project will inform on the current state of success of ARV&#xD;
      treatments in this population. Moreover, the other goal of this study is to conclude on the&#xD;
      need to conduct a larger study at the national or regional level according to the results&#xD;
      obtained&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">January 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 14, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Viral load suppression after ≥ 6 months of antiretroviral therapy</measure>
    <time_frame>Day 0</time_frame>
    <description>Proportion of participants with HIV-1 RNA &lt;1000 copies / ml after ≥ 6 months of antiretroviral therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug resistance after ≥ 6 months of antiretroviral therapy</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of participants with HIV-1 RNA ≥ 300 copies / ml and presence of antiretroviral-resistant virus (ARV) after ≥ 6 months of antiretroviral therapy</description>
  </secondary_outcome>
  <enrollment type="Anticipated">289</enrollment>
  <condition>HIV-1-infection</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will include adolescents living with HIV infection, aged 10 to 19 years and&#xD;
        follow-up in a treatment unit in Douala, Cameroon.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Being adolescent (aged 10 to 19) on antiretroviral therapy and followed at the&#xD;
             Laquintinie Hospital (Douala Cameroon)&#xD;
&#xD;
          -  HIV-1 infection&#xD;
&#xD;
          -  Duration of antiretroviral therapy ≥ 6 months regardless of antiretroviral regimen&#xD;
&#xD;
          -  For emancipated adolescents: obtaining informed consent signed by the adolescent&#xD;
&#xD;
          -  For unemancipated adolescents:&#xD;
&#xD;
          -  Obtaining informed consent signed by the legal representative (parent(s) or&#xD;
             guardian(s))&#xD;
&#xD;
          -  Obtaining the assent of adolescents able to understand the study (maturity and&#xD;
             knowledge of HIV status)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infection with HIV-1 or HIV-1/HIV2 co-infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Avelin F AGHOKENG, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut de Recherche pour le Developpement</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ida C PENDA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Laquinitie de Douala</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Avelin F AGHOKENG, PhD</last_name>
    <phone>+(33)467415958</phone>
    <email>avelin.aghokeng@ird.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ida C PENDA, PhD</last_name>
    <phone>+(237)7770 31 55</phone>
    <email>calix.penda@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Laquinitie de Douala</name>
      <address>
        <city>Douala</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ida C Penda, PhD</last_name>
      <phone>+(237)7770 31 55</phone>
      <email>calix.penda@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Cameroon</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Virological failure</keyword>
  <keyword>HIV drug resistance</keyword>
  <keyword>Adolescents</keyword>
  <keyword>Cameroon</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>To be decided later</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

